Abstract
Death-domain receptor 3 (DR3)variants having increased binding affinity to TL1A,and composition comprising same,are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.
| Original language | English |
|---|---|
| Patent number | CA2947255 |
| IPC | A61P 29/ 00 A I |
| Priority date | 27/04/15 |
| State | Published - 5 Nov 2015 |